학술논문
An EORTC-ECSG phase I study of LU 79553 administered every 21 or 42 days in patients with solid tumours
Document Type
Article
Author
Source
In European Journal of Cancer April 2003 39(6):742-747
Subject
Language
ISSN
0959-8049